PMID- 26303404
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20181202
IS  - 1873-4847 (Electronic)
IS  - 0955-2863 (Linking)
VI  - 26
IP  - 11
DP  - 2015 Nov
TI  - n-3 polyunsaturated fatty acids stimulate osteoclastogenesis through 
      PPARgamma-mediated enhancement of c-Fos expression, and suppress osteoclastogenesis 
      through PPARgamma-dependent inhibition of NFkB activation.
PG  - 1317-27
LID - S0955-2863(15)00156-4 [pii]
LID - 10.1016/j.jnutbio.2015.06.007 [doi]
AB  - n-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA) and 
      docosahexaenoic acid (DHA) have been reported to suppress osteoclastogenesis in 
      vivo. In this study, the effect of PUFAs on receptor for activation of nuclear 
      factor-kappaB ligand (RANKL)-induced osteoclastogenesis was examined using bone 
      marrow-derived monocytes/macrophage precursor cells (BMMs) or bone marrow cells 
      (BMCs) in vitro. EPA and DHA stimulated the osteoclastic differentiation of BMMs, 
      but n-6 PUFAs, linoleic acid and arachidonic acid had no effect. The stimulation 
      of osteoclastogenesis of BMMs by EPA and DHA was associated with enhancement of 
      the gene expressions of c-Fos, tartrate-resistant acid phosphatase, cathepsin K 
      and peroxisome proliferator-activated receptor-gamma (PPARgamma) and the protein levels 
      of c-Fos, PPARgamma and nuclear factor of activated T cells, cytoplasmic, 
      calcineurin-dependent-1 (NFATc1). The PPARgamma agonists, rosiglitazone and GW1929, 
      also stimulated the osteoclastogenesis of BMMs. The PPARgamma antagonists, T0070907 
      and GW9662, inhibited the stimulations of osteoclastogenesis and c-Fos expression 
      by EPA or DHA. However, EPA and DHA inhibited the osteoclastogenesis in BMCs 
      including BMMs and mesenchymal stem cells (MSCs). This inhibition was associated 
      with suppression of the expression of RANKL and nuclear factor-kappaB 
      (NFkappaB)-regulating genes, cyclooxygenase 2, TNFalpha and IL-6 in BMCs and MSCs. The 
      agonists and antagonists of PPARgamma showed that the inhibitions of NFkappaB 
      transcriptional activity and osteoclastogenesis by EPA and DHA were 
      PPARgamma-dependent. These results suggest that EPA and DHA directly act on BMMs and 
      stimulate osteoclastogenesis through enhancing c-Fos expression mediated by PPARgamma 
      but suppress osteoclastogenesis through the PPARgamma-dependent inhibition of NFkappaB 
      activation of MSCs in BMCs.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Nakanishi, Atsuko
AU  - Nakanishi A
AD  - Department of Food Science and Nutrition, Nara Women's University, Kita-uoya 
      Nishi-machi, Nara, 630-8506, Japan.
FAU - Tsukamoto, Ikuyo
AU  - Tsukamoto I
AD  - Department of Food Science and Nutrition, Nara Women's University, Kita-uoya 
      Nishi-machi, Nara, 630-8506, Japan; Faculty of Clinical Nutrition, Hiroshima 
      International University, 5-1-1, Hirokoshingai, Kure, Hiroshima, 737-0112, Japan. 
      Electronic address: itsuka@cc.nara-wu.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20150726
PL  - United States
TA  - J Nutr Biochem
JT  - The Journal of nutritional biochemistry
JID - 9010081
RN  - 0 (Benzophenones)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (NF-kappa B)
RN  - 0 (NFATC1 protein, rat)
RN  - 0 (PPAR gamma)
RN  - 0 (Proto-Oncogene Proteins c-fos)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Transcription Factors)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - 42HK56048U (Tyrosine)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (Ptgs2 protein, rat)
RN  - X8S066WKF4 (GW 1929)
SB  - IM
EIN - J Nutr Biochem. 2016 Apr;30:189
MH  - Animals
MH  - Benzophenones/pharmacology
MH  - Bone Marrow Cells/cytology/drug effects/physiology
MH  - Cells, Cultured
MH  - Cyclooxygenase 2/genetics/metabolism
MH  - Docosahexaenoic Acids/pharmacology
MH  - Eicosapentaenoic Acid/pharmacology
MH  - Fatty Acids, Omega-3/*pharmacology
MH  - Gene Expression Regulation/drug effects
MH  - Male
MH  - Mesenchymal Stem Cells/drug effects
MH  - NF-kappa B/*metabolism
MH  - Osteogenesis/*drug effects/genetics
MH  - PPAR gamma/agonists/antagonists & inhibitors/genetics/*metabolism
MH  - Proto-Oncogene Proteins c-fos/genetics/*metabolism
MH  - Rats, Wistar
MH  - Rosiglitazone
MH  - Thiazolidinediones/pharmacology
MH  - Transcription Factors/genetics/metabolism
MH  - Tyrosine/analogs & derivatives/pharmacology
OTO - NOTNLM
OT  - Bone marrow-derived monocytes/macrophage precursor cells (BMMs)
OT  - Docosahexaenoic acid (DHA)
OT  - Eicosapentaenoic acid (EPA)
OT  - Osteoclastogenesis
OT  - PPARgamma
OT  - c-fos
EDAT- 2015/08/26 06:00
MHDA- 2017/09/26 06:00
CRDT- 2015/08/26 06:00
PHST- 2015/01/27 00:00 [received]
PHST- 2015/06/17 00:00 [revised]
PHST- 2015/06/17 00:00 [accepted]
PHST- 2015/08/26 06:00 [entrez]
PHST- 2015/08/26 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
AID - S0955-2863(15)00156-4 [pii]
AID - 10.1016/j.jnutbio.2015.06.007 [doi]
PST - ppublish
SO  - J Nutr Biochem. 2015 Nov;26(11):1317-27. doi: 10.1016/j.jnutbio.2015.06.007. Epub 
      2015 Jul 26.